TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05478668

Intervention type: OTHER
Intervention: visual analog scale
Description: In all patients, the assessment of anesthetic risk was carried out according to the ASA scale. The basic tool for pain intensity research was a visual analog scale. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the Didier Bouhassiraa neuropathic pain diagnostic questionnaire. Study of the presence of an acute stress reaction The Hospital Anxiety and Depression Scale. Research on the presence of post-traumatic stress disorders was carried out using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.

Intervention type: OTHER
Intervention: visual analog scale
Description: In all patients, the assessment of anesthetic risk was carried out according to the ASA scale. The basic tool for pain intensity research was a visual analog scale. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the Didier Bouhassiraa neuropathic pain diagnostic questionnaire. Study of the presence of an acute stress reaction The Hospital Anxiety and Depression Scale. Research on the presence of post-traumatic stress disorders was carried out using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
Study: NCT05132517

Intervention type: DIAGNOSTIC_TEST
Intervention: Kölner Neuropsychologische Screening für Schlaganfall-Patienten
Description: The cognitive state of the patient is measure by the Kölner Neuropsychologische Screening (KöpSS) and by the Mini Mental Status Test (MMST). The MMST is a popular often used test, which makes comparisons to other international studies possible. However, even though this test was specifically designed for stroke patients, it has a limited sensibility. Thus the KöpSS is being used as an additional test demonstrating satisfactory sensibility and specificity. It is suitable for acute and subacute strokes and covers all stroke relevant domains.
Study: NCT05944341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: articaine hydrochloride 4% with epinephrine 1:100 000
Description: Local anesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: articaine hydrochloride 4% with epinephrine 1:100 000
Description: Local anesthetic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 2% with epinephrine 1:100 000
Description: Local anesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine hydrochloride 2% with epinephrine 1:100 000
Description: Local anesthetic agent
Study: NCT05976464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate in erector spinae plane block
Description: Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on the surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine into interfacial plane below erector spinae muscle.~General anesthesia will be induced with l/kg fentanyl, 2mg/kg propofol, 0.5 mg/kg atracurium and inhalational anesthesia (sevoflurane) No other narcotic, analgesic or sedative will be administrated during the operative period.~BP(SystolicBP, DiastolicBP) and HR will be observed and recorded every 30 min till the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate in erector spinae plane block
Description: Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on the surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine into interfacial plane below erector spinae muscle.~General anesthesia will be induced with l/kg fentanyl, 2mg/kg propofol, 0.5 mg/kg atracurium and inhalational anesthesia (sevoflurane) No other narcotic, analgesic or sedative will be administrated during the operative period.~BP(SystolicBP, DiastolicBP) and HR will be observed and recorded every 30 min till the end of surgery.
Study: NCT05304156

Intervention type: OTHER
Intervention: Biobanking blood and bone marrow specimens
Description: Interventions, procedures added for research purposes :~Blood Samples :~* Peripheral blood (20mL EDTA) (at Screening, pre-ICT Day 1, Day1 H8, Day 2, Day 3, Day 4 and Day of EOI evaluation~Bone Marrow samples :~* Biopsy at Screening and at EOI Evaluation~* Additional volume (2mL EDTA) on the Screening,2 and EOI Evaluation aspirations for single-cell analyses.~* Aspiration at D8 for Smears and 2 mL EDTA for single-cell analyses (instead of D15 standard care).
Study: NCT05252221

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ATC Intervention
Description: The ATC intervention offers convenient access to specialty consultation for PCPs and offers patients direct access to addiction treatment in a non-stigmatized primary care setting
Study: NCT04861246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: The device will be used to do Laser treatment. To compare the therapeutic effect to laser treatment before and post treatment for 14 and 60 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ApolloVue® S100 Image System
Description: The device is an in vivo non-invasive optical coherence tomography and will be used to obtain OCT images before and after laser treatment of skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VISIA®
Description: The device is skin analysis system and will be used to obtain before and after images of laser treatment.
Study: NCT05541159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: Single oral dose of TNO155 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: Single oral dose of TNO155 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: Single oral dose of TNO155 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: Single oral dose of TNO155 on Day 1
Study: NCT06351735

Intervention type: PROCEDURE
Intervention: Deep cervical lymph node-vein bypass surgery
Description: Deep cervical lymph node-vein bypass surgery, connecting deep cervical lymph node input lymphatic vessel
Study: NCT04494087

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explanatory video
Description: Links to explanatory videos handed out to patients to be watched at home after standard informed consent giving

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Explanatory video
Description: Links to explanatory videos handed out to patients to be watched at home after standard informed consent giving

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Informed consent form
Description: Links to a digital version of the informed consent form already discussed during the process of informed consent giving.
Study: NCT04772287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Toripalimab mimetic (placebo)
Description: Placebo: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.
Study: NCT05408676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electric stimulation therapy
Description: Transcutaneous electrical acupoint stimulation (TEAS) was achieved by an electrical neuromuscular stimulation device (JNR2; designed by the Department of Hand Surgery, Huashan Hospital, Fudan University, manufactured by Energy Conservation and Environment Protection Technology Company, Jiatong University, Shanghai,China)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: electric stimulation therapy
Description: Transcutaneous electrical acupoint stimulation (TEAS) was achieved by an electrical neuromuscular stimulation device (JNR2; designed by the Department of Hand Surgery, Huashan Hospital, Fudan University, manufactured by Energy Conservation and Environment Protection Technology Company, Jiatong University, Shanghai,China)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: electric stimulation therapy
Description: Transcutaneous electrical acupoint stimulation (TEAS) was achieved by an electrical neuromuscular stimulation device (JNR2; designed by the Department of Hand Surgery, Huashan Hospital, Fudan University, manufactured by Energy Conservation and Environment Protection Technology Company, Jiatong University, Shanghai,China)
Study: NCT05780099

Intervention type: OTHER
Intervention: Inpatient or Outpatient visit
Description: Patients will be seen and treated at the clinics like in the usual care
Study: NCT05899946

Intervention type: OTHER
Group type: OTHER
Intervention: A community-based network training program
Description: A 3-phase program including establishing a community-based network, video competition, and Video promotions will be conducted.
Study: NCT05530889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST Lens
Description: ACUVUE® Theravision® with Ketotifen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST Lens
Description: ACUVUE® Theravision® with Ketotifen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL Lens
Description: 1-DAY ACUVUE® MOIST.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL Lens
Description: 1-DAY ACUVUE® MOIST.
Study: NCT05229263

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non- contrast Enhanced Multiparametric Renal Magnetic Resonance
Description: MRI is performed in a single multiparametric scan session with no need for contrast agents, and to depict changes in tissue microstructure associated with inflammation and fibrosis plus alterations in oxygenation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non- contrast Enhanced Multiparametric Renal Magnetic Resonance
Description: MRI is performed in a single multiparametric scan session with no need for contrast agents, and to depict changes in tissue microstructure associated with inflammation and fibrosis plus alterations in oxygenation.
Study: NCT05625009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery: Transversus Abdominis Plane Block (TAPB)
Description: Patients received TAPB postoperatively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery: Erector Spinae Plane Block (ESPB)
Description: Patients received ESPB postoperatively
Study: NCT04812457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hialucic
Description: A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the intervention group, an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
Study: NCT04996888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI based preoperative automatic reminder system
Description: the patients in the experimental group will be sent a message and a phone call by AI system on the day before colonoscopy, which will emphasize the importance of bowel preparation, the directions for use and side effects of purgatives, the proper food type, and the start time. The system is an non-invasive AI system.
Study: NCT04812457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betadine gel
Description: A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the control group, Betadine Gel will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
Study: NCT05021692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based support program for pregnant women with preeclampsia based on the Health Promotion Model
Description: support program
Study: NCT06065410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Walking without any instruction or sound
Study: NCT06087900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate continuous training (MICT)
Description: The participants received a moderate continuous training (MICT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 50 minutes of exercise at 65-70% of maximal heart rate, and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise increases to 70-75% of maximal heart rate at week 7-12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: The participants received a 7x2 high intensity interval training (HIIT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 28 minutes of exercise (2 minutes of high intensity at 85-90% of maximal heart rate interval with 2 minutes of low intensity at 50-55% of maximal heart rate 7 times), and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise at high intensity increases to 90-95% of maximal heart rate at week 7-12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Description: The participants received Powerbreathe ® ClassicLight in this training program. The IMT group demonstrated the training 8 cycles of 30 breath, 5 days/week with progressive load 50% of maximal inspiratory pressure (MIP) at week 1-3, 60% of MIP at week 4-6, 70% of MIP at week 7-9, and 80% of MIP at week 10-12. Every first day of the week participants had to undergoing load adjustment at laboratory

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The CON group did not have any intervention but usual care.
Study: NCT06147687

Intervention type: DIAGNOSTIC_TEST
Intervention: Self reported data collection
Description: ML assessement of colleceted data

Intervention type: DIAGNOSTIC_TEST
Intervention: Self reported data collection
Description: ML assessement of colleceted data
Study: NCT04498377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F-652
Description: IL-22 fusion protein administered intravenously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously
Study: NCT06508606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: AK117: 45mg/kg (D1, IVGTT, Q3W maintained for one year or until progression or intolerable toxicity occurred

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-EGFR
Description: anti-EGFR:initial dose 400mg/m2, subsequent doses of 250mg/m2, D1, QW) maintained for one year or until progression or intolerable toxicity occurred
Study: NCT06508684

Intervention type: DRUG
Intervention: BTK inhibitor
Description: BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
Study: NCT04728594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Proof
Description: Email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reframing
Description: Email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scarcity Message
Description: Email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scarcity Message
Description: Email
Study: NCT06065410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrinsic focus
Description: Walking focusing on ensuring equal step lengths and step durations on both sides and symmetry between both steps
Study: NCT05857904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-FFR
Description: CT -FFR(coronary computed tomography angiography drived fractional flow reserve derived) uses routine coronary computed tomography angiography (CTA) images and applies a specific algorithm to extract both anatomical and physiological information of the coronary arteries. By combining these two pieces of information, a fluid dynamics model of the coronary arteries can be established, allowing the calculation of FFR at any location of the coronary arteries.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QFR
Description: Quantitative flow ratio (QFR) is a new method for evaluating the functional significance of coronary artery stenosis based on angiography. It can be used for real-time detection of hemodynamic abnormalities in the coronary arteries in the catheterization lab. Unlike traditional methods that require the use of pressure wires and vasodilators such as adenosine, the QFR examination process only requires routine coronary angiography. By reconstructing the three-dimensional structure of the blood vessels and analyzing the hemodynamics, the QFR can evaluate the fractional flow reserve (FFR) without the need for pressure wires and vasodilators.
Study: NCT06508931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zamtocabtagene autoleucel (MB-CART2019.1)
Description: Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy.
Study: NCT01196494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraoperative colon lavage with primary anastomosis
Description: Patients with obstructive left-sided colonic cancer in wich treatment in one stage procedure is intraoperative colon lavage with primary anastomosis to avoid Hartamnn´s Procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative colon lavage with primary anastomosis
Description: Patients with obstructive left-sided colonic cancer in wich treatment in one stage procedure is intraoperative colon lavage with primary anastomosis to avoid Hartamnn´s Procedure
Study: NCT06065410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White noise
Description: Intrinsic focus accompanied by white noise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: environmental sound
Description: Intrinsic focus accompanied by environmental sound
Study: NCT05737277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapral
Description: This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period
Study: NCT04825990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab every 3 weeks plus 300 mg olaparib twice a day (BID) every day starting from Day 1 of Cycle 1.
Study: NCT06129110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Weight Loss
Description: Low calorie diet of meal replacement shakes
Study: NCT05809804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.